BRPI0914662A2 - derivados de triazinona substituída - Google Patents
derivados de triazinona substituídaInfo
- Publication number
- BRPI0914662A2 BRPI0914662A2 BRPI0914662A BRPI0914662A BRPI0914662A2 BR PI0914662 A2 BRPI0914662 A2 BR PI0914662A2 BR PI0914662 A BRPI0914662 A BR PI0914662A BR PI0914662 A BRPI0914662 A BR PI0914662A BR PI0914662 A2 BRPI0914662 A2 BR PI0914662A2
- Authority
- BR
- Brazil
- Prior art keywords
- triazinone derivatives
- substituted
- substituted triazinone
- derivatives
- triazinone
- Prior art date
Links
- QMNWYGTWTXOQTP-UHFFFAOYSA-N 1h-triazin-6-one Chemical class O=C1C=CN=NN1 QMNWYGTWTXOQTP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290617A EP2138488A1 (en) | 2008-06-26 | 2008-06-26 | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
PCT/IB2009/006463 WO2009156860A2 (en) | 2008-06-26 | 2009-06-25 | Substituted triazinone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0914662A2 true BRPI0914662A2 (pt) | 2015-10-20 |
Family
ID=39832570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0914662A BRPI0914662A2 (pt) | 2008-06-26 | 2009-06-25 | derivados de triazinona substituída |
Country Status (23)
Country | Link |
---|---|
US (1) | US8592580B2 (pt) |
EP (2) | EP2138488A1 (pt) |
JP (1) | JP5581318B2 (pt) |
KR (1) | KR20110025219A (pt) |
CN (1) | CN102137854A (pt) |
AR (1) | AR072227A1 (pt) |
AT (1) | ATE538114T1 (pt) |
AU (1) | AU2009263846A1 (pt) |
BR (1) | BRPI0914662A2 (pt) |
CA (1) | CA2729115A1 (pt) |
CY (1) | CY1112642T1 (pt) |
DK (1) | DK2321295T3 (pt) |
EA (1) | EA201170095A1 (pt) |
ES (1) | ES2379220T3 (pt) |
IL (1) | IL210174A0 (pt) |
MX (1) | MX2010014235A (pt) |
NZ (1) | NZ590116A (pt) |
PL (1) | PL2321295T3 (pt) |
PT (1) | PT2321295E (pt) |
SI (1) | SI2321295T1 (pt) |
TW (1) | TW201004935A (pt) |
WO (1) | WO2009156860A2 (pt) |
ZA (1) | ZA201100026B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2138493A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
EP2138498A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
EP2138485A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
EP2138492A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
EP2138495A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
EP2138494A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP6304492B2 (ja) * | 2012-03-30 | 2018-04-04 | 日産化学工業株式会社 | トリアジノン化合物及びt型カルシウムチャネル阻害剤 |
SI3459942T1 (sl) * | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
SG11201507203RA (en) | 2013-03-12 | 2015-10-29 | Vertex Pharma | Dna-pk inhibitors |
JP6408569B2 (ja) | 2013-10-17 | 2018-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Dna−pk阻害剤としての(s)−n−メチル−8−(1−((2’−メチル−[4,5’−ビピリミジン]−6−イル)アミノ)プロパン−2−イル)キノリン−4−カルボキサミドおよびその重水素化誘導体の共結晶 |
TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
EP3154953B1 (en) * | 2014-06-13 | 2018-04-04 | Fondazione Istituto Italiano di Tecnologia | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease |
SG11201800698VA (en) * | 2015-08-17 | 2018-03-28 | Japan Tobacco Inc | Hydroxytriazine compound and medical use thereof |
US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
WO2022152138A1 (zh) * | 2021-01-15 | 2022-07-21 | 中国医药研究开发中心有限公司 | 稠和杂环类化合物及其制备方法和医药用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5170780A (ja) * | 1974-12-17 | 1976-06-18 | Nippon Shinyaku Co Ltd | Shinkinabenzoguanidoruino seiho |
EG13192A (en) | 1976-02-10 | 1982-12-31 | Rhone Poulenc Ind | Nouveaux derives du dithiole-1,2 leur preparation et les compositions qui les contiennent |
HU178496B (en) | 1977-12-29 | 1982-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 6,7,8,9-tetrahydro-4h-pyrido/1,2-a/pyrimidine derivatives with antiallergic activity |
US4406897A (en) | 1981-07-06 | 1983-09-27 | William H. Rorer, Inc. | 6-Aryl-4-hydrazinyl-s-triazin-2-ones |
US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
WO1997016430A1 (en) | 1995-11-01 | 1997-05-09 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
IL123986A (en) | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
EP1136484A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Arylalkylamino)pyrimidone derivatives |
CA2665516A1 (en) | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
MXPA04002632A (es) | 2001-09-21 | 2004-07-08 | Mitsubishin Pharma Corp | Derivados de 2-pirimidinil-6,7,8,9-tetrahidropirimido-[1,2-a] pirimidin-4-ona y 7-pirimidinil-2,3. dihidroimidazo [1,2-a] pirimidim-5 (1h)-ona substituidos para desordenes neurodegenerativos. |
CA2495661C (en) | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
EP1454909B1 (en) | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
EP1460076A1 (en) | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
EA017545B1 (ru) * | 2005-06-30 | 2013-01-30 | Янссен Фармацевтика Н.В. | Циклические анилино-пиридинотриазины в качестве ингибиторов gsk-3 |
EP1790649A1 (en) | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituted bicyclic pyrimidone derivatives |
ATE530540T1 (de) * | 2006-08-23 | 2011-11-15 | Pfizer Prod Inc | Pyrimidonverbindungen als gsk-3-inhibitoren |
US20110039893A1 (en) * | 2006-10-11 | 2011-02-17 | Takeda Pharmaceutical Company Limited | Gsk-3beta inhibitor |
EP1992624A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
EP2138492A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
EP2138495A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
-
2008
- 2008-06-26 EP EP08290617A patent/EP2138488A1/en not_active Withdrawn
-
2009
- 2009-06-24 TW TW098121235A patent/TW201004935A/zh unknown
- 2009-06-24 AR ARP090102315A patent/AR072227A1/es unknown
- 2009-06-25 KR KR1020117001908A patent/KR20110025219A/ko not_active Withdrawn
- 2009-06-25 PT PT09769671T patent/PT2321295E/pt unknown
- 2009-06-25 MX MX2010014235A patent/MX2010014235A/es not_active Application Discontinuation
- 2009-06-25 AU AU2009263846A patent/AU2009263846A1/en not_active Abandoned
- 2009-06-25 CA CA2729115A patent/CA2729115A1/en not_active Abandoned
- 2009-06-25 WO PCT/IB2009/006463 patent/WO2009156860A2/en active Application Filing
- 2009-06-25 DK DK09769671.0T patent/DK2321295T3/da active
- 2009-06-25 PL PL09769671T patent/PL2321295T3/pl unknown
- 2009-06-25 JP JP2011515667A patent/JP5581318B2/ja not_active Expired - Fee Related
- 2009-06-25 AT AT09769671T patent/ATE538114T1/de active
- 2009-06-25 NZ NZ590116A patent/NZ590116A/en not_active IP Right Cessation
- 2009-06-25 SI SI200930201T patent/SI2321295T1/sl unknown
- 2009-06-25 BR BRPI0914662A patent/BRPI0914662A2/pt not_active IP Right Cessation
- 2009-06-25 EP EP09769671A patent/EP2321295B1/en active Active
- 2009-06-25 CN CN2009801334844A patent/CN102137854A/zh active Pending
- 2009-06-25 ES ES09769671T patent/ES2379220T3/es active Active
- 2009-06-25 EA EA201170095A patent/EA201170095A1/ru unknown
-
2010
- 2010-12-15 US US12/968,935 patent/US8592580B2/en not_active Expired - Fee Related
- 2010-12-22 IL IL210174A patent/IL210174A0/en unknown
-
2011
- 2011-01-03 ZA ZA2011/00026A patent/ZA201100026B/en unknown
-
2012
- 2012-03-16 CY CY20121100288T patent/CY1112642T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AR072227A1 (es) | 2010-08-11 |
CN102137854A (zh) | 2011-07-27 |
TW201004935A (en) | 2010-02-01 |
EP2321295B1 (en) | 2011-12-21 |
KR20110025219A (ko) | 2011-03-09 |
EA201170095A1 (ru) | 2011-08-30 |
CY1112642T1 (el) | 2016-02-10 |
ES2379220T3 (es) | 2012-04-23 |
PL2321295T3 (pl) | 2012-06-29 |
ATE538114T1 (de) | 2012-01-15 |
JP2011525905A (ja) | 2011-09-29 |
US8592580B2 (en) | 2013-11-26 |
DK2321295T3 (da) | 2012-04-10 |
JP5581318B2 (ja) | 2014-08-27 |
IL210174A0 (en) | 2011-03-31 |
CA2729115A1 (en) | 2009-12-30 |
WO2009156860A3 (en) | 2010-03-04 |
AU2009263846A1 (en) | 2009-12-30 |
EP2138488A1 (en) | 2009-12-30 |
US20110144114A1 (en) | 2011-06-16 |
PT2321295E (pt) | 2012-03-23 |
MX2010014235A (es) | 2011-06-24 |
WO2009156860A2 (en) | 2009-12-30 |
ZA201100026B (en) | 2012-04-25 |
EP2321295A2 (en) | 2011-05-18 |
SI2321295T1 (sl) | 2012-04-30 |
NZ590116A (en) | 2011-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0914662A2 (pt) | derivados de triazinona substituída | |
FR24C1047I1 (fr) | Derive de 4-pyrimidinesulfamide | |
BRPI0907435A2 (pt) | Derivados de 5-flúor pirimidina | |
BRPI0914544A2 (pt) | derivados de pirimidona substituídos | |
BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
BRPI0820112A2 (pt) | Derivados de isoxazol-piridina | |
BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
EP2376493A4 (en) | DIHYDROPYRIMIDOPYRIMIDINDERIVAT | |
DK2308877T3 (da) | Imidazopyridin-2-on-derivater | |
EP2380877A4 (en) | PYRIDINE-3-CARBONSÄUREAMIDDERIVAT | |
BRPI0812155A2 (pt) | derivados de espiroindolinona | |
BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
BRPI0817935A2 (pt) | Derivados de biarila | |
EP2226315A4 (en) | 2-aminoquinazoline DERIVATIVE | |
BRPI0923497A2 (pt) | derivados de piridazinona | |
BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
BRPI0906436A2 (pt) | Derivados de ftalazinona | |
BRPI0909527A2 (pt) | derivados substituídos de 4-aminociclohexano | |
DK2340021T3 (da) | Substituerede pyrrolidin-2-carboxamider | |
BRPI0812518A2 (pt) | Derivados de indazolamida | |
BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
EP2336132A4 (en) | MORPHOLINPURINDERIVAT | |
BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |